N@N

PRE, AUXL, WRI, VVUS, ARRY, L Expected To Be Down After Next Earnings Releases

^{Published on 2011-10-28 05:21:51 - WOPRAI}
 

October 28, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Monday, October 31st 2011 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports. PARTNERRE LTD (NYSE:PRE), AUXILIUM PHARMACEUTICALS INC (NASDAQ:AUXL), WEINGARTEN REALTY INVESTORS (NYSE:WRI), VIVUS INC (NASDAQ:VVUS), ARRAY BIOPHARMA INC (NASDAQ:ARRY), LOEWS CORP (NYSE:L) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Monday:

     Symbol     Company                             # of Reports            Quarter     Release Time
     PRE        PARTNERRE LTD                       6 Quarter               Q3          After
     AUXL       AUXILIUM PHARMACEUTICALS INC        6 Quarter               Q3          Before
     WRI        WEINGARTEN REALTY INVESTORS         6 Quarter               Q3          Before
     VVUS       VIVUS INC                           12 Quarter              Q3          After
     ARRY       ARRAY BIOPHARMA INC                 6 Quarter               Q1          After
     L          LOEWS CORP                          6 Quarter               Q3          Before

PARTNERRE LTD (NYSE:PRE) - PartnerRe Ltd., through its subsidiaries, provides reinsurance solutions worldwide. The company offers property reinsurance coverage to insurers for property damage or business interruption losses resulting from fires, catastrophes, and other perils covered in industrial and commercial property, and homeowners policies; and casualty reinsurance products, which include third party liability, employers liability, workers compensation, and personal accident coverage. It also provides motor reinsurance coverage for third party liability and property damage risks arising from passenger and commercial fleet automobile coverage written by cedants; specialized reinsurance protection for airline, general aviation, and space insurance business; and coverage against agricultural yield and price/revenue risks related to flood, drought, and hail, as well as diseases related to crops, livestock, and aquaculture; and property catastrophe reinsurance protection against the accumulation of losses caused by windstorm, earthquake, and flood or by any other natural hazard. In addition, the company provides credit/surety reinsurance coverage to commercial credit insurers, bonds, and other forms of security; reinsurance for engineering projects; reinsurance coverage for onshore oil and gas, mining, power generation, and pharmaceutical operations; and reinsurance protection and technical services relating to marine hull, cargo, transit, and offshore oil and gas operations. Further, it offers reinsurance protection for non-U.S. property and casualty business, as well as reinsurance coverage to primary life insurers and pension funds with respect to individual and group life and health risks. The company offers its services directly, as well as through brokers. PartnerRe Ltd. was founded in 1993 and is based in Pembroke, Bermuda.

AUXILIUM PHARMACEUTICALS INC (NASDAQ:AUXL) - Auxilium Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company primarily in the United States. It focuses on developing and marketing products to urologists, endocrinologists, primary care physicians, hand surgeons, and rheumatologists, as well as to orthopedic, general, and plastic surgeons. The company markets XIAFLEX (collagenase clostridium histolyticum), an injectable collagenase enzyme for the treatment of adult Dupuytrens contracture; and Testim, a topical 1% testosterone gel for the treatment of hypogonadism. The companys clinical development products include XIAFLEX that is in Phase III clinical trials for the treatment of Peyronies disease, as well as in Phase II clinical trials for the treatment of Adhesive Capsulitis. In addition, it has rights to develop other products for the treatment of pain, urologic disease, and hormone replacement using its transmucosal film delivery system. The company has a strategic alliance with Asahi Kasei Pharma Corporation for the development, commercialization, and supply of XIAFLEX, a biologic for the treatment of Dupuytrens contracture and Peyronies disease. Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania.

WEINGARTEN REALTY INVESTORS (NYSE:WRI) - Weingarten Realty Investors operates as a real estate investment trust (REIT). The company engages in the management, acquisition, and development of real estate. It operates in two segments, Shopping Center and Industrial. The Shopping Center segment engages in the acquisition, development, and management of real estate, primarily anchored neighborhood and community shopping centers located in Texas, California, Louisiana, Arizona, Nevada, Arkansas, New Mexico, Oklahoma, Tennessee, Kansas, Colorado, Missouri, Illinois, Florida, North Carolina, Mississippi, Georgia, Utah, Kentucky, and Maine. Its customer base includes supermarkets, discount retailers, drugstores, and other retailers. The Industrial segment engages in the acquisition, development, and management of bulk warehouses and office/service centers. Its properties are located in Texas, Nevada, Georgia, Florida, California, and Tennessee. As of June 30, 2005, Weingarten Realty Investors owned or operated under long-term leases, directly or through its interest in joint ventures or partnerships, a total of 350 developed properties and 3 properties that are in various stages of development. Its properties include 294 shopping centers and 59 industrial properties. Weingarten Realty Investors qualifies as a REIT for federal income tax purposes. As a REIT, it would not be taxed on the portion of its income, which is distributed to shareholders, provided it distributes at least 90% of its taxable income. The company was founded in 1948 and is based in Houston, Texas.

VIVUS INC (NASDAQ:VVUS) - VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for underserved markets in the United States. It offers MUSE, a minimally invasive therapy for erectile dysfunction. The companys investigational product pipeline includes Qnexa that has completed Phase 3 clinical trials for obesity, and Phase 2 clinical trials for diabetes and obstructive sleep apnea; Avanafil, which is in phase 3 clinical trials to treat erectile dysfunction; and Luramist, which has completed phase 2 clinical trials for the treatment of hypoactive sexual desire disorder in women. It has a development, licensing, and supply agreement with Tanabe Seiyaku Co., Ltd. for the development and commercialization of Avanafil; and licensing agreements with Acrux and its subsidiary to develop and commercialize Luramist and Evamist in the United States. The company was founded in 1991 and is headquartered in Mountain View, California.

ARRAY BIOPHARMA INC (NASDAQ:ARRY) - Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer, inflammatory, and metabolic diseases in North America, Europe, and Asia Pacific. Its programs under development pipeline include ARRY-403, a glucokinase activator for Type 2 diabetes, that is in a Phase 1 multiple ascending dose trial; ARRY-162, a MEK inhibitor for cancer that is in a Phase 1 trial; ARRY-380, an ErbB-2 inhibitor for breast cancer, which is in Phase 1 dose escalation trial; and ARRY-520, a KSP inhibitor that is in Phase 1 expansion trial in solid tumors and Phase 1/2 acute myeloid leukemia and multiple myeloma trials. The companys programs also comprise ARRY-614, a p38/Tie 2 dual inhibitor, which is in Phase 1 trial in myelodysplastic syndrome patients; ARRY-543, an ErbB family (ErbB-2/EGFR) inhibitor for solid tumors that is in Phase 1b combination trials; ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications; and ARRY-300, an MEK that completed Phase 1 trial in healthy volunteers. It has collaborations with Celgene Corporation focusing on the discovery, development, and commercialization of novel therapeutics in cancer and inflammation; Genentech, Inc. to develop cancer programs; and AstraZeneca, PLC, which licensed the companys three MEK inhibitors for cancer, including AZD6244 (ARRY-886). The company was founded in 1998 and is headquartered in Boulder, Colorado.

LOEWS CORP (NYSE:L) - Loews Corporation, through its subsidiaries, operates primarily as a commercial property and casualty insurance company in the United States. It provides professional liability and other coverages through property and casualty products and services; surety and fidelity bonds, and vehicle warranty services; and risk management, information, warranty, and claims administration services. The company also offers standard and excess property, marine, and boiler and machinery coverages; workers compensation coverage; general and product liability products; and commercial, auto, and umbrella coverages, as well as long term care, group reinsurance, and life settlement contracts. In addition, it owns and operates offshore drilling rigs that are used in the drilling of offshore oil and gas wells on a contract basis for companies engaged in the exploration and production of hydrocarbons. As of December 31, 2009, the company owned 47 offshore drilling rigs. Further, Loews Corporation engages in the exploration, production, and marketing of natural gas, natural gas liquids, and oil. It held interests in the properties located in Permian Basin in Texas, the Antrim Shale in Michigan, and the Black Warrior Basin in Alabama; and had net proved reserves of approximately 2.0 trillion cubic feet of natural gas equivalent. Additionally, the company involves in the interstate transportation and storage of natural gas. It owned and operated 14,200 miles of interconnected pipelines carrying approximately 2.1 trillion cubic feet of gas to customers in the northeastern and southeastern United States, and underground storage fields with aggregate working gas capacity of approximately 163.0 billion cubic feet of natural gas. Loews Corporation also operated 18 hotels in the United States and Canada. The company was founded in 1954 and is headquartered in New York, New York.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641